Mithridion

Mithridion

closed
Mithridion develops drugs for central nervous system disorders, with special focus on schizophrenia and Alzheimer's disease.

Launch date
Employees
Market cap
-
Enterprise valuation
€5—7m (Dealroom.co estimates Jan 2011.)
Madison Wisconsin (HQ)
Authorizing premium user...